Applications of Gene Therapy - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 308

[91] Stewart AK, Lassam NJ, Quirt IC, Bailey DJ, Rotstein LE, Krajden M, et al.
Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and
melanoma: results of a phase 1 clinical trial. Gene Ther 1999;6:350-63.
[92] Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, et al. Interleukin 12 gene
therapy of cancer by peritumoral injection of transduced autologous fibroblasts: out-
come of a phase I study. Hum Gene Ther 2001;12:671-84.
[93] Rosenberg SA, Anderson WF, Asher LA, Blaese MR, Ettinghausen SE, Hwu P, et al.
Immunization of cancer patients using autologous cancer cells modified by insertion of
the gene for tumor necrosis factor. Hum Gene Ther. 1992;3:1-57.
[94] Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the
immunotherapy and gene therapy of cancer. Gene Ther 1995;2:96-106.
[95] Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, et al.
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy
in patients with localized malignancy: results of a phase I clinical trial in malignant
mesothelioma. Hum Gene Ther 1998;9:1083-92.
[96] Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a
frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-4.
[97] Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T, Roth JA. Stable expression of the wild-
type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum
Gene Ther 1993;4:617-24.
[98] Gavrieli Y, Sherman Y, BenSasson SA. Identification of programmed cell death in situ
via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
[99] Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen Schaub LB, Roth JA.
Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-medi-
ated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-91.
[100] Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M. Adenovirally transferred
p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat
Med 1997;3:313-19.
[101] Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al.
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.
Nat Med 1996;2:985-91.
[102] Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, et al. Gene
therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adeno-
viral p53 gene replacement. Semin Oncol 1998;25:33-7.
[103] Schuler M, Rochlitz C, Horowitz JA, Schlegel J, Perruchoud AP, Kommoss F, et al.
A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with
advanced non-small cell lung cancer. Hum Gene Ther 1998;9:2075-82.
[104] Inoue A, Narumi K, Matsubara N, Sugawara S, Saijo Y, Satoh K, et al. Administration
of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-can-
cer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett
2000;157:105-12.
[105] Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, et al.
Adenovirus- mediated p53 gene transfer in sequence with cisplatin to tumors of patients
with non-small-cell lung cancer. J Clin Oncol 2000;18:609-22.
[106] Moon C, Oh Y, Roth JA. Current status of gene therapy for lung cancer and head and
neck cancer. Clin Cancer Res 2003;9:5055-67.
[107] Dosaka AH, Akie K, Hiroumi H, Kinoshita I, Kawakami Y, Murakami A. Inhibition of
proliferation by L-myc antisense DNA for the translational initiation site in human small
cell lung cancer. Cancer Res 1995;55:1559-64.